Betaine compositions

Pharmaceutical unit dosage form comprising at least a pharmaceutical combination containing at least:

• A first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and
• A second compound selected from the group consisting of lipidic betaines, betaines lipid, betaines of formula (CH3)3N+(CH2)nCOO− with n an integer from 1 to 5, or a pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the provision that said second compound is different from the first compound, in which the combination is prepared from a mixture in which the first compound and the second compound are partly in a soluble form.

Pharmaceutical unit dosage form comprising at least a pharmaceutical combination containing at least:

• a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and
• a second compound selected from the group consisting of lipidic betaines, betaines lipid, betaines of formula (CH3)3N+(CH2)nCOO− with n an integer from 1 to 5, or a pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound, in which the combination is prepared from a mixture in which the first compound and the second compound are partly in a soluble form.

A kit for a daily administration, said kit comprising at least:

• a first oral formulation comprising a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof, and
• a second oral formulation comprising a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula (CH3)3N+(CH2)nCOO− with n an integer from 1 to 5, or a pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound in which the first oral formulation comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound in the second oral formulation is at least Fe five times the amount, calculated as acetylsalicylic acid, of said first compound.

(canceled)

Process of treatment of a patient in need for treating, preventing, reducing inflammation troubles in a patient, by administering to said patient a pharmaceutical mbinai an rding t P anne +f the lains 1 te 15 or a phaace eutica d d ese according to anyone of the clas 16 to 7 less than 100 ml of a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, and pharmaceutical derivatives thereof and in which advargeeusly bf and/r during ande,r a.ter said adminit n, a therapeutic effective amount of glycine betaine is further administered to said patient said amount of glycine betaine is at least 5 times the amount, calculated as acetylsalicylic acid weight of said first compound.

A pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer in an amount at least three times the amount of aspirin.

A pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer in an amount at least e five times the amount of aspirin.

The pharmaceutical composition as defined in claim +50 in the form of a bilayered tablet which comprises a first layer comprising aspirin granules and at least one or more excipient e ns, and a second layer comprising a betaine and at least one of m buffering compound eempounds and at least one or more excipient Recipients.

A pharmaceutical composition comprising betaine and aspirin in a formulation to reduce aspirin side effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

A pharmaceutical composition comprising betaine and aspirin in a formulation to reduce aspirin side effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

A pharmaceutical composition comprising betaine and aspirin in a formulation to increase aspirin therapeutic effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

A pharmaceutical composition comprising betaine and aspirin in a formulation to increase aspirin therapeutic effects wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer.

What we claim is:

The use of

• a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
• a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula (CH3)3N+(CH2)nCOO— with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound, for the preparation of a pharmaceutical unit dosage form for treating or preventing blood flow disturbances, said unit dosage form comprising at least a first compound, and a second compound, in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

The use of

• a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
• a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula (CH3)3N+(CH2)nCOO— with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound, for the preparation of a pharmaceutical unit dosage form for treating or preventing cancer, said unit dosage form comprising at least a first compound and a second compound, in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

The use of

• a first compound selected among the group consisting acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and
• a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of formula (CH3)3N+(CH2)nCOO— with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that said second compound is different from the first compound, for the preparation of a pharmaceutical unit dosage form for treating or preventing diabetes, said unit dosage form comprising at least:
• a first compound and a second compound, in which said unit dosage form comprises less than 100 mg of said first compound expressed as acetylsalicylic acid, and in which the amount of second compound is at least 5 times the amount, calculated as acetylsalicylic acid weight, of said first compound.

A method for reducing risk of an event selected from the group consisting of cardiovascular events, coronary artery troubles and cerebro-vascular troubles, which comprises administering to the patient at risk of such an event a therapeutically effective amount of a pharmaceutical composition comprising a betaine and aspirin in a formulation wherein the betaine and aspirin are formulated together in a bilayered tablet, the aspirin being present in a first layer, and the betaine being present in a second layer in an amount at least five times the amount of aspirin.